ASA issues top five 'Choosing wisely' recommendations

ASA issues top five <i>Choosing wisely</i> recommendations

(HealthDay)—The top five anesthesiology-related pain medicine issues that physicians and patients should question have been released by the American Society of Anesthesiologists (ASA) as part of the Choosing Wisely campaign.

The ASA Committee on Pain Medicine submitted potential recommendations and voted on which issues should be included in the top five. Supporting evidence was identified from literature searches.

The top five recommendations include: (1) opioid analgesics should not be prescribed as first-line therapy for treatment of non-cancer pain; (2) should not be prescribed as long-term treatment for chronic non-cancer pain treatment until the risks have been considered and discussed with the patient; (3) imaging studies such as , computed tomography, or X-ray should be avoided for acute without specific indications; (4) intravenous sedation should not be used as a default practice for diagnostic and therapeutic nerve blocks or joint injections; and (5) irreversible interventions for non-cancer pain that carry considerable costs and/or risks should be avoided.

"As leaders in patient safety, physician anesthesiologists want the most effective tests and treatments for our patients and we want them to be used appropriately," Jane C.K. Fitch, M.D., president of the ASA, said in a statement. "ASA has taken the lead in improving patient safety related to anesthesiology and ."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

SGO issues top five Choosing Wisely recommendations

Nov 06, 2013

(HealthDay)—The top five gynecologic oncology-related issues that physicians and patients should question have been released by the Society of Gynecologic Oncology (SGO) as part of the Choosing Wisely campai ...

AAFP issues top five 'choosing wisely' recommendations

Feb 26, 2013

(HealthDay)—The top five primary care issues that patients and physicians should question have been released by the American Academy of Family Physicians (AAFP) as part of the Choosing Wisely Campaign.

Recommended for you

Added benefit of vedolizumab is not proven

36 minutes ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments